Overview

Eflornithine in Treating Patients With Bladder Cancer

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Eflornithine